Giredestrant Promising New Treatment For Early-Stage HR-Positive Breast Cancer
Published on December 10, 2025
After surgery, many people with stage I to stage III hormone receptor-positive breast cancer take tamoxifen or an aromatase inhibitor for five to 10 years. This has been the standard of care for the last 25 years.
At the 2025 San Antonio Breast Cancer Symposium, UCLA scientist Dr. Aditya Bardia presented results on giredestrant, a new oral selective estrogen degrader/downregulator (SERD) that offered better disease-free survival — how long people live without the cancer returning – than tamoxifen or an aromatase inhibitor.
Listen to the episode to hear Dr. Bardia explain:
how giredestrant is different from the two other available SERDs
if giredestrant could be combined with a CDK4/6 inhibitor
giredestrant side effects
what the results mean for people diagnosed with early-stage hormone receptor-positive breast cancer
Scroll down to below the “About the guest” information to read a transcript of this podcast.
Dr. Aditya Bardia is director of the Breast Oncology Program and Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, where he is also professor of medicine in hematology/oncology at the David Geffen School of Medicine at UCLA.
This podcast episode is made possible by Lilly.
Your donation goes directly to what you read, hear, and see on Breastcancer.org.